Obinutuzumab in Combination with Alternative Chlorambucil Schedules in Front-Line Treatment of Chronic Lymphocytic Leukemia: A Study by KroHem, the Croatian Cooperative Group for Hematologic Diseases

<b>Background/Objectives</b><i>:</i> Obinutuzumab was approved for front-line treatment of chronic lymphocytic leukemia in combination with chlorambucil pulses administered every 2 wks. Alternative schedules of chlorambucil enable the administration of higher total chlorambucil doses, and have bette...

Descripció completa

Dades bibliogràfiques

Autors principals:	Igor Aurer, Ozren Jakšić, Sandra Bašić-Kinda, Karla Mišura-Jakobac, Jasminka Sinčić-Petričević, Sabina Novaković-Coha, Davor Galušić, Hrvoje Holik, Toni Valković, Dubravka Županić-Krmek, Ida Hude-Dragičević, Vibor Milunović, Vlatko Pejša
Format:	Artigo
Idioma:	Inglês
Publicat:	MDPI AG 2024-12-01
Col·lecció:	Biomedicines
Matèries:	chronic lymphocytic leukemia obinutuzumab chlorambucil
Accés en línia:	https://www.mdpi.com/2227-9059/12/12/2902
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!